Italia markets close in 4 hours 3 minutes

Organovo Holdings, Inc. (0R02.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
1,2700+0,0900 (+7,63%)
In data: 06:43PM BST. Mercato aperto.
Schermo intero
Chiusura precedente1,1800
Aperto0,0000
Denaro0,0000 x N/D
Lettera0,0000 x N/D
Min-Max giorno0,0000 - 0,0000
Intervallo di 52 settimane
Volume1.800
Media Volume565
Capitalizzazione710.845
Beta (5 anni mensile)0,90
Rapporto PE (ttm)N/D
EPS (ttm)-1,3150
Prossima data utili11 lug 2024 - 15 lug 2024
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Organovo to Participate in the H.C. Wainwright Global Investment Conference

    SAN DIEGO, Sept. 08, 2023 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO) (Organovo), a clinical stage biotechnology company that is focused on developing novel human therapies with high fidelity in three-dimensional (3D) human tissues that recapitulate key aspects of human disease, today announced that Keith Murphy, Founder and Executive Chairman, will present a corporate update and hold meetings with institutional investors during the H.C. Wainwright 25th Annual Global Investment Co

  • GlobeNewswire

    Organovo Advances Clinical Timelines for FXR314 and Provides Updates on NASH Phase 2 Data

    SAN DIEGO, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO) (Organovo), a clinical stage biotechnology company that is focused on developing novel human therapies with demonstrated function in high fidelity three-dimensional (3D) tissues that recapitulate key aspects of human disease, today announced more details about its clinical program for FXR314, an FXR agonist that has completed initial clinical trials. FXR314 is a drug with safety and tolerability after daily oral